Zhang W, et al. - Given that dendritic cell (DC) vaccines prepared with Wilms’ tumor protein 1 (WT1) peptides have been highly effective in cancers, researchers focused on the outcomes of a DC-based vaccination for advanced breast, ovarian, and gastric cancers in a phase 1/2 study. This clinical study included 10 patients who were treated biweekly with a WT1 peptide-pulsed DC vaccination; toxicity and clinical and immunological responses were assessed. In an adjuvant setting, the reported adverse events to DC vaccinations were tolerable. Seven patients had stable disease. Enhanced Karnofsky Performance Scale scores were seen, and computed tomography-detected tumor shrinkage was noted in three of these seven patients. Overall, WT1 peptide-pulsed DC vaccination is a potential treatment for advanced cancer.